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ABSTRACT* 
Provision of medication information may improve 
adherence and prevent medication related 
problems. People with mental health disorders 
commonly receive less medication counselling from 
pharmacists than people with other common long 
term and persistent disorders. 
Objective: The objective of this study was to 
compare and contrast barriers pharmacy students 
perceive toward providing medication counselling 
for people with mental health disorders in Australia, 
Belgium, Estonia, Finland, India and Latvia. 
Methods: Barriers identified by third-year pharmacy 
students as part of the International Pharmacy 
Students’ Health Survey were content analysed 
using a directed approach. Students’ responses 
were categorised as pharmacist related, patient 
related, health-system related, or social or cultural 
related. Quantitative data were analysed using 
SPSS version 14.0. 
Results: Survey instruments were returned by 649 
students. Of the respondents, 480 identified one or 
more barriers to medication counselling for people 
with mental health disorders. Patient related factors 
accounted for between 25.3% and 36.2% of barriers 
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identified by the pharmacy students. Pharmacist 
related factors accounted for between 17.6% and 
45.1% of the barriers identified by the pharmacy 
students. Students in India were more likely to 
attribute barriers to pharmacist and social and 
cultural related factors, and less likely to health-
system related factors, than students studying in 
other countries. 
Conclusion: The nature of barriers identified by 
pharmacy students differed according to the country 
in which they studied. Undergraduate and 
postgraduate pharmacy education programs may 
need to be amended to address common 
misconceptions among pharmacy students. 
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BARRERAS AL CONSEJO SOBRE 
MEDICAMENTOS PARA PERSONAS CON 
DESORDENES MENTALES: UN ESTUDIO 
EN SEIS PAÍSES 
 
RESUMEN 
La provisión de información sobre medicamentos 
puede mejorar la adherencia y prevenir problemas 
relacionados con los medicamentos. Las personas 
con desordenes mentales normalmente reciben 
menos consejos sobre medicación de los 
farmacéuticos que la gente con otras enfermedades 
comunes de larga duración. 
Objetivo: El objetivo de este estudio fue comparar 
y contrastar las barreras que los estudiantes de 
farmacia perciben hacia proporcionar consejos de 
medicación para personas con desordenes mentales 
en Australia, Bélgica, Estonia, Finlandia, India y 
Letonia. 
Métodos: Se realizó un análisis de contenido de 
abordaje directo de las barreras identificadas pro 
estudiantes de tercero de farmacia como parte de la 
Encuesta de Salud de los Estudiantes de Farmacia. 
Las respuestas de los estudiantes se categorizaron 
como relativas al farmacéutico, relativas al 
paciente, relativas al sistema de salud, o relativas a 
aspectos sociales o culturales. Los datos 
cuantitativos se analizaron utilizando un SPSS 
versión 14.0. 
Resultados: Las encuestas fueron retornadas por 
649 estudiantes. De los respondentes, 480 
identificaron una o más barreras al consejo sobre 
medicación para personas con desordenes mentales. 
Los factores relativos al paciente representaron 
entre el 25,3% y el 36,2% de las barreras 
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identificadas por los estudiantes. Los factores 
relativos al farmacéutico alcanzaron el 17,6% a 
45,1% de las barreras identificadas. Los estudiantes 
de India eran más proclives a atribuir barreras al 
farmacéutico y a los aspectos sociales y culturales, 
y menos a los factores del sistema de salud que los 
estudiantes de otros países. 
Conclusión: La naturaleza de las barreras 
identificadas por los estudiantes de farmacia difirió 
entre los países estudiados. Los programas de 
formación pre y postgraduados en farmacia podrían 
tener que corregirse para encarar los malos 
entendidos comunes entre los estudiantes de 
farmacia. 
 
Palabras clave: Desordenes mentales. Servicios de 
farmacia comunitaria. Actitudes del personal 







Mental health disorders represent a major public 
health problem that is often neglected by clinicians 
and policy makers. Despite being responsible for a 
high level of disability, mental health disorders are 
often under-recognised and under-treated in high, 
middle and low income countries.1 Mental and 
behavioural disorders are present in 10% of the 
adult population at any one point in time, and 
mental health disorders contribute more than 12% 
of global disease burden.2 Mental health disorders 
account for 31% years lived with disability 
worldwide and 43% of years lived with disability in 
Europe and North America.3 The Mental Health 
Action Plan for Europe recognises the importance of 
developing primary mental health care services, 
including the need to provide greater access to 
psychotropic medications in community settings.4 
The development of community pharmacy services 
for people with mental health disorders is consistent 
with the need to improve models of primary mental 
health care. People experiencing psychiatric 
symptoms may seek help from community 
pharmacists without consulting other health care 
professionals.5 Services provided by pharmacists 
are well suited to optimising the use of medications 
for mental health disorders.6-8 Medications are often 
the patient and health care professional preferred 
treatments for severe or persistent major depressive 
and psychotic disorders. However, people taking 
psychotropic medications for mental health 
disorders are at high risk of experiencing medication 
related problems.9 Estimates of medication non-
adherence among Department of Veterans Affairs 
patients taking antipsychotics and mood stabilisers 
in the United States are greater than 40%.10,11 
Similarly high rates of treatment discontinuation 
have been reported during the acute and 
continuation phases of antidepressant treatment.12 
Provision of medication information has been 
identified as a key strategy to improve medication 
adherence and prevent adverse drug events.13,14 
Medication counselling provided by community 
pharmacists is an important source of medication 
information for patients and their caregivers.15 
Community-pharmacy based medication 
counselling interventions have resulted in improved 
patient adherence to antidepressant and 
antipsychotic medications.16,17  
People with mental health disorders may receive 
less medication information from pharmacists and 
physicians than people taking medications for other 
long-term and persistent conditions.18,19 
Pharmacists are required by law to offer medication 
counselling when dispensing medications in 
countries including Finland and the United 
States.20,21 However, pharmacists have reported 
feeling less confident and may be less likely to 
provide medication information to people with 
mental health disorders than to those with 
cardiovascular conditions, diabetes or asthma.22,23 
People with mental health disorders have reported 
their dissatisfaction with the quality and quantity of 
medication information provided by their health 
professionals.24 Focus groups with pharmacists 
have suggested sub-optimal attitudes and poor 
communication with people with mental health 
disorders may limit service provision to this patient 
population.25 In one study, people collecting 
prescriptions for fluoxetine were less likely to 
receive medication counselling when served by 
pharmacy staff aged over 50 years or when visiting 
a pharmacy with 10 or fewer employees.26 
Stigmatising attitudes toward people with 
schizophrenia have been associated with less 
positive attitudes toward providing concordant 
medication counselling.27 The need for education to 
address the barriers to the provision of primary 
mental health care has been described.28 However, 
few studies have assessed the barriers to 
pharmacists’ medication counselling for people with 
mental health disorders.23,29  
International diagnostic and treatment 
recommendations are primarily based on North 
American and Western European experiences of 
mental health disorders.30,31 There is a lack of 
evidence pertaining to barriers and facilitators of 
mental health care in other countries. The 
importance of incorporating issues of race, culture 
and ethnicity into mental health services research, 
teaching and clinical practice is gaining 
recognition.32-34 Culture may contribute to 
differences in help-seeking, diagnosis and 
treatment. The attitudes of pharmacy students 
toward people with mental health disorders may 
differ according to the country in which they study.35 
The objective of this study was to investigate the 
barriers pharmacy students perceive toward 
providing medication counselling for people with 
mental health disorders in Australia, Belgium, 
Estonia, Finland, India and Latvia. 
 
METHODS  
Study design and data collection  
Data for the study were collected between February 
2006 and May 2007 as part of the International 
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Pharmacy Students’ Health Survey (IPSHS). This 
was a one-time census survey of third-year 
pharmacy students studying at eight universities in 
six countries. The aim of the survey was to assess 
respondents’ attitudes and willingness to provide 
pharmaceutical care to people with mental health 
disorders.35 The sample of universities that 
participated in the survey was a convenience 
sample, but comprised educational institutions that 
were diverse in their geographical location, teaching 
language, and the cultural backgrounds of the 
enrolled students. Third-year students were 
selected as the study population because under the 
Bologna Declaration, an agreement to create a 
common framework for higher education across 
Europe36, this is the final year of study for those 
students undertaking the Bachelor of Pharmacy 
degree. All universities that participated in our study 
provided education related to mental ill-health and 
psychiatric medications, however, the format and 
duration of this education varied between 
universities. All students were invited to voluntarily 
complete the survey instrument in hard copy during 
a lecture or tutorial held at their respective 
university. 
Survey instrument 
Overall the survey instrument comprised 55 items, 
including one open-ended question. In addition to 
items concerning the demographic characteristics of 
the respondents, the survey instrument included the 
seven-item Social Distance Scale (SDS), 14-item 
Leeds Attitudes Toward Concordance (LATCon) 
scale, two multiple choice items regarding causes of 
disability, seven-items about the provision of 
pharmaceutical services, and 16 items concerning 
mental health stigma. A copy of the survey 
instrument can be obtained by contacting the 
corresponding author. This paper reports the 
analysis of open-ended question of the IPSHS. The 
survey instrument was administered in English or in 
an official language of the respective country. The 
wording of the item was adapted from an earlier 
survey of pharmacists’ attitudes toward providing 
pharmaceutical care to users of psychiatric 
medications.22  
The wording of the item was: 
 - “In community pharmacy, what factors do you 
think make it more difficult to provide medication 
counselling to patients with mental health 
condition/s?”(in English) 
- ”Miksi avoapteekissa on vaikea antaa 
lääkeneuvontaa mielenterveyspotilaille?” (in 
Finnish)  
- ”Millised tegurid muudavad uldapteegis vaimsete 
häiretega patsientide raviminoustamise raskeks?” 
(in Estonian) 
The English version of the survey instrument was 
used at The University of Sydney, Katholieke 
Universiteit Leuven, Bombay College of Pharmacy, 
Dr. L.H. Hiranandani College of Pharmacy, 
University of Latvia and Riga Stradins University. 
The survey instrument was translated into Finnish 
for use at the University of Helsinki and Estonian for 
use at the University of Tartu. The translations were 
performed using a back-translation protocol.37 The 
translated versions of the survey instrument were 
pilot tested for face-validity using a convenience 
sample of pharmacy students or graduates. 
Data analyses  
Students’ responses to the open-ended question 
were content analysed using a directed 
approach.38,39 A model related to cultural 
competency in healthcare published by the 
Commonwealth Fund40, and previous research 
about the role of the pharmacist in providing care for 
people with schizophrenia and depression23,29,41, 
were used to inform the design of the coding 
framework. The directed approach, which is more 
structured than conventional content analysis, was 
chosen due to the brevity of the students’ responses 
and the opportunity to utilise previously published 
research literature to inform the development of the 
framework. This method facilitated quantitative 
comparisons between students’ responses in each 
of the participating countries. The coding system 
was based on the principle that barriers to 
medication counselling could be classified as 
pharmacist related, patient related or health-system 
related. Once coding commenced, the need for an 
additional code related to social and cultural barriers 
became evident. Thus all students’ responses were 
recoded using one of four mutually exclusive codes 
(pharmacist related, patient related, health-system 
related, and social or cultural related). 
Due to the low numbers of third year pharmacy 
students studying in Estonia and Latvia, data from 
these two Baltic States were pooled to facilitate 
comparisons to responses obtained from students 
studying in Finland, Australia and India. All 
quantitative data were analysed using SPSS 
version 14.0 (Chicago, IL). The demographic 
information was tabulated. Demographic 
characteristics (gender, birthplace, work experience 
in a pharmacy and the percentage of students who 
self-reported that they themselves had suffered a 
mental illness) of the responders and non-
responders to the open-ended were compared 
using chi-squared tests (except where one cell had 
a value of less than 5, in which case a Fisher's 
Exact Test was used). The mean ages of the 
responders and non-responders were compared 
using Mann-Whitney U tests for each country. The 
level of significance was set at 0.05. 
Ethical considerations 
The study was approved by the Human Research 
Ethics Committee at the University of Sydney and 
the Institutional Review Board at Riga Stradins 
University. The study was deemed exempt from 
requiring ethics approval by the Katholieke 
Universiteit Leuven, University of Helsinki, Bombay 
College of Pharmacy, Dr. L.H. Hiranandani College 
of Pharmacy, University of Latvia and the University 
of Tartu. All study procedures were conducted in 
accordance with the World Medical Association 
Declaration of Helsinki. 
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RESULTS  
Survey instruments were returned by students from 
Australia (n=241, 98% response rate), Belgium 
(n=102, 74%), Estonia and Latvia (n=70, 86% 
response rate), Finland (n=130, 81% response rate) 
and India (n=106, 91% response rate). However, 
not all students who returned the survey instrument 
responded to the open-ended question. Responses 
to the open-ended question were received from 
students in Australia (n=188), Belgium (n=40), 
Estonia and Latvia (n=39), Finland (n=114) and 
India (n=85). There were no significant differences 
in terms of gender, age, birthplace, previous work 
experience in pharmacy or the percentages of 
students who reported that they themselves had 
suffered a mental illness, between the responders 
and non responders to the open-ended question. 
Respondents from Finland were older, more likely to 
be female, to have worked in a pharmacy and to 
report personal experience of mental illness than 
students studying in other countries (Table 1). With 
the exception of respondents from Australia, more 
than 98% of students were born in the country in 
which they studied. 
Patient related factors accounted for between 
25.3% and 36.2% of barriers identified by the 
pharmacy students (Table 2). Examples of barriers 
coded as patient related included the belief that 
people with mental health disorders would not be 
willing to receive or incapable of understanding 
medication information (Table 3). Pharmacist 
related factors accounted for between 17.6% and 
45.1% of the barriers identified by the pharmacy 
students. Barriers coded as pharmacist related 
included the pharmacists’ lack of knowledge or 
confidence, and the attitudes of pharmacists toward 
people with mental health disorders. Health-system 
related factors accounted for between 4.6% and 
36.8% of the barriers identified by the pharmacy 
students. Health-system related barriers included 
lack of time and privacy in community pharmacies, 
community pharmacists not having access to 
patients’ medical and/or medication records, and 
the perception it is the role of the physician to 
provide information about medications. Social and 
cultural barriers accounted for between 8.9% and 
21.6% of the barriers identified by the pharmacy 
students. Social and cultural barriers included 
language barriers between the pharmacist and 
patient. Students studying in India were more likely 
than students studying in Australia, Belgium, 
Finland or Estonia and Latvia to attribute barriers to 
pharmacist related factors and social or cultural 
factors (Table 3). Patient related factors were most 
frequently identified by Finnish students and health-
system related factors by Australian students. 
 
DISCUSSION 
Barriers perceived by pharmacy students in our 
study were broadly consistent with those identified 
by practising pharmacists in Canada and the United 
Kingdom.23,29,41 These common issues, such as 
lack of adequate knowledge about mental health 
disorders were recognised at each study site.  













N Valid % N Valid % N Valid % N Valid % N Valid % 
Gender              
  Male 67 36 10 25 10 26 11 10 36 42 
  Female 121 64 30 75 29 74 103 90 49 58 
Age (yrs)               
  Mean 21  21  23  25  20  
  Range  18-38  20-28  20-37  21-50  19-23  
Birthplace              
  Australia 98 52         
  Belgium   39 98       
  Estonia     15 38     
  Finland        114 100   
  India         85 100 
  Latvia     24 62     
  Other 90 48 1 2       
Work experience in a 
pharmacy 
          
  Yes 138 73 2 5 24 62 114 100 7c 8 
  No 50 27 38 95 15 38 0 0 76 92 
Students self-reporting 
they had suffered a 
mental illness      
          
  Yes 12a 7  4 10 1 3 14b 12 2 2 
  No 173 94 36 90 38 97 99 88 83 98 
a. 3 students did not respond to this item 
b. 1 student did not respond to this item 
c. 2 students did not respond to this item 
d. University of Sydney 
e. Katholieke Universiteit Leuven 
f. University of Tartu; University of Latvia; Riga Stradins University 
g. University of Helsinki 
h. Bombay College of Pharmacy; Dr. L.H. Hiranandani College of Pharmacy 
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Nevertheless, there were also differences in barriers 
perceived by pharmacy students in each country. 
A common patient related barrier in all countries 
was the belief that symptoms of the mental health 
disorders and/or side effects of medication 
treatments would mean that people would not 
understand the information provided by 
pharmacists. While some psychotropic medications 
may impair cognitive function, this barrier may 
reflect a misconception on behalf of the students. 
This is consistent with previous research that 
suggested many pharmacy students may not 
understand the nature of mental health disorders.35 
A proportion of Australian pharmacy students and 
graduates indicated in a previous study that people 
with severe depression and schizophrenia are hard 
to talk to or that they should ‘pull themselves 
together’.42 Another patient related barrier was the 
perception that people with mental health disorders 
would not be interested to receive medication 
information. This finding has also been reported in a 
study of Dutch pharmacists who believed that 
people with schizophrenia would be disinterested to 
receive medication information.43 This belief is at 
odds with the unmet need for medication 
information commonly reported among this patient 
population.24,25,43 Frustration with the lack of 
information provided by health professionals may be 
a reason people with mental health disorders 
frequently seek information using the internet and 
from telephone-based information services.44-46 
Previous research has suggested that people from 
non-western ethnic backgrounds are more likely 
blame people with mental health disorders for 
having their condition.47 This was not; however, 
reflected in higher number patient related barriers 
being identified by students from non-western 
backgrounds. People with mental health disorders 
in non-western societies may attract community 
support.48 Respondents from India emphasised the 
role of family members and caregivers as recipients 
of medication counselling. In contrast, people from 
western societies may prioritise the autonomy of 
individuals. 
Table 2. Percentage of patient-related, pharmacist-related, health-system  related and social and cultural related barriers identified 













Patient-related factors 33.1 25.3 33.9 36.2 28.8 
Patients not willing to communicate  
Patient perception about the role of pharmacists  
Not interested to receive medication counselling 
Symptoms of disorder means not able to understand 
information  
Side-effects of medication means patient not able to 
understand information 
Medication already familiar to the patient  
     
Pharmacist-related factors 17.6 36.0 30.4 29.3 45.1 
Lack of confidence, knowledge or skill 
Attitudes and beliefs of the pharmacist 
Business motives of pharmacists 
Uncertainty about conducting counselling for family members 
and caregivers 
Need to provide counselling to family members and caregivers 
only 
     
Health-system related factors 36.8 28.0 26.8 22.9 4.6 
Lack of privacy in community pharmacies 
Lack of time 
Role of physician to provide information about medications 
Pharmacists not having access to medical histories 
Poor communication between pharmacists and physicians 
Poor communication between physicians and patients 
The high cost of medications means patients not able to follow 
advice 
Lack of mental health education available for healthcare 
professionals 
     
Social or cultural related factors 12.5 10.7 8.9 11.7 21.6 
Stigma surrounding mental disorders 
Language barriers 
Cultural barriers 
Different interpretations about causes and prognosis of mental 
disorders 
 
     
a. Some students identified more than one barrier.  
b  University of Sydney 
c  Katholieke Universiteit Leuven 
d  University of Tartu; University of Latvia; Riga Stradins University 
e  University of Helsinki 
f  Bombay College of Pharmacy; Dr.L.H.Hiranandani College of Pharmacy 
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Pharmacists’ uncertainty in relation to the role of 
family members and caregivers were classified as 
pharmacist related barrier. Students in India 
reported being particularly uncertain about how 
much medication counselling to provide to family 
members and caregivers of people with mental 
health disorders. The role of family members in 
caring for people with mental health disorders may 
be different in India than in the other countries the 
study was conducted.49,50 In India family may be 
expected to be involved in care of people with 
mental health disorders; thus, there may be a need 
to involve family members in decisions related to 
medications.50,51 This may not be the case in the 
other countries. Several Indian students also 
believed that pharmacists should only provide 
medication counselling to family members or 
caregivers. This belief may have arisen from the 
perception that providing medication counselling to 
people with mental health disorders may decrease 
medication adherence52, a perception that is not 
necessarily supported by research evidence.53 
Perceived lack of knowledge and skill to provide 
medication counselling to people with mental health 
disorders was common pharmacist related barrier 
identified by students in all countries. Pharmacy 
education in many countries remains primarily 
focused on the pharmacological properties of 
medications rather than the needs and experiences 
of people taking when these medications. Students 
commonly reported the need to better understand 
the psychology of mental health disorders. New 
models of pharmacy education may be required to 
provide students with an insight into people’s 
experience of their illness. Although medical 
students’ attitudes may improve over the course of 
medical education54, this finding was not replicated 
in a study of pharmacy students’ attitudes.42 Greater 
consumer involvement in development and delivery 
of mental health pharmacy education may be one 
effective strategy to improve the attitudes of 
pharmacy students toward people with mental 
health disorders.55 
Students in India were more likely to attribute 
barriers to pharmacist related factors and less likely 
to health-system related factors than students 
studying in other countries. Students studying in 
India were least likely to have worked in a pharmacy 
and, therefore, may have been less likely to cite 
barriers related to the health-system factors. Lack of 
work experience in pharmacies may also have 
restricted their ability to identify health-system 
related barriers. Additionally, the Bachelor of 
Pharmacy degree program in India is primary 
focused on preparing graduates to work within the 
pharmaceutical industry. 
A common health-system related barrier identified 
by the students studying in Australia, Belgium, 
Estonia and Latvia was lack of privacy. This barrier 
has also been reported by Canadian pharmacists.29 
This finding may highlight a shortcoming in the 
layout and design of community pharmacies in 
these countries. Despite recent initiatives to improve 
the layout of pharmacies in Australia, the majority of 
community pharmacies lack private areas for 
conducting medication counselling at the time of 
dispensing. A greater number of Finnish 
pharmacies include purpose built counselling 
stations designed to protect patient privacy. The 
need to ensure patient privacy in community 
pharmacies is also enacted in Finnish law.20 In 
contrast, few Indian students identified lack of 
privacy as a barrier to the provision of medication 
counselling. This was likely due to underlying beliefs 
about the relative need for privacy rather than the 
layout of community pharmacies in India. 
Pharmacists not having access to medication 
histories, medical histories or patient diagnostic 
data were commonly cited health-system related 
barriers in relation to providing medication 
counselling. The development and implementation 
Table 3. Examples of patient-related, pharmacist-related, health-system related and social and cultural related barriers to 
medication counselling  
Patient-related factors 
• “Patients are unwilling/uncomfortable talking about their condition” (Australia) 
• “Patients and their family members not willing to talk about medications” (India)  
• “Any patient with a mental health condition is not in a stable condition, so he won’t percept any changes in his treatment if 
he is informed about his condition” (India) 
• “Patients who suffer from a mental health condition may not understand when a normal person speaks” (India)  
• “Patients with mental illness know themselves what they need or at least they think so” (Belgium) 
• “These patients would not listen to or believe the pharmacist” (Estonia) 
Pharmacist-related factors  
 “Pharmacists need more education about the psychology of mental illness rather than just knowing about the D2 antagonist” 
(Australia) 
• “A pharmacist must first understand the psychology of the patient” (India) 
• “Hesitation of the pharmacist towards people with mental health conditions…” (India) 
• “Pharmacists are afraid to be connected with such people” (Latvia)  
• “…pharmacists need to be more careful than for people with other health problems” (Finland) 
Health-system related factors  
• “The physician should explain about the medication” (Latvia) 
• “In the presence of other people [in the pharmacy], patients with mental disorders may feel uncomfortable” (Estonia) 
• “Lack of private counselling areas in community pharmacies” (Australia) 
• “You don’t know the cause of the depression…” (Belgium) 
Social or cultural related factors  
• “Our society and environment is mainly responsible for barriers to providing medication counselling” (India) 
• “Mental health is a taboo subject in our country” (Finland) 
• “Language barriers”  (Australia) 
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of electronic patient record systems may provide 
community pharmacists with access to more 
accurate and comprehensive medication histories. 
This may facilitate the improved provision of 
medication counselling to people with mental health 
disorders. However, existing electronic patient 
record systems in pharmacies may be incomplete 
and require pharmacists to be more proactive and 
systematic when gathering patient information.56 
Electronic patient record systems may improve 
communication between pharmacists and 
physicians if pharmacists are able to add their own 
notices about patients’ medication to the records, 
such as side-effects or interactions. However, this 
does not remove the need to build clear agreement 
of the roles of physician and pharmacist in 
managing patients’ medication therapy. One 
common health-system related barrier identified by 
pharmacy students was the impression that it is 
physicians’ responsibility to provide counselling 
about the medication. A survey conducted in 1994 
revealed that despite pharmacists’ medication 
counselling being mandated in law, many Finnish 
physicians believed that pharmacists should be 
cautious when discussing the indication of 
psychotropic medications, especially neuroleptics, if 
the indication is not specified on the prescription.52 
While it is not clear how many physicians retain 
these views, these findings support the need to find 
consensus about the roles and responsibilities of 
pharmacists and physicians concerning medication 
counselling. 
Language was a social and cultural barrier to 
medication counselling identified by Australian 
students. Australia is recognised for its cultural 
diversity (as reflected in the fact approximately half 
the Australian pharmacy student respondents in our 
study were not born in Australia). The need to 
consider culture and language when conducting 
medication counselling has received recent 
attention.57-59 This may be particularly true in 
relation to people with mental health disorders. In 
contrast, Belgium, Estonia, Finland, India and Latvia 
are more homogenous in terms of the nationalities 
of the inhabitants. These countries may include 
people from a variety of cultural and religious 
backgrounds from within the country. A recent study 
indicated ethnic Russians living in Estonia were less 
satisfied with medication information provided in 
community pharmacies than ethnic Estonians.59 
However, few Estonian or Latvian students cited 
cultural barriers in relation to providing medication 
counselling to people with mental health disorders. 
Limitations  
Not all universities offering pharmacy education in 
Australia, Belgium, Finland and India participated in 
the IPSHS, and thus, the results may not be 
generalisable to all pharmacy students within these 
countries. It is possible that students from urban 
and rural backgrounds perceived different barriers, 
although this was not explored in the present study. 
The term mental disorders refers to a diverse range 
of neuropsychiatric disorders with some 
commonalities.60 It is not known whether barriers 
pharmacy students perceive to medication 
counselling differed accordingly to the type of 
mental disorder. Despite students studying in Latvia 
and Estonia likely having different cultural 
backgrounds, data from these two Baltic States 
were pooled. The numbers of respondents from 
these countries individually were otherwise 
insufficient to facilitate meaningful comparison. 
Future studies are needed to determine whether 
students’ self-perceived barriers to medication 
counselling differ in Latvia and Estonia. 
The directed coding of responses facilitated an 
informed approach to data interpretation. However, 
a limitation of the directed content analytic approach 
was that some of the nuances in the data may have 
been lost.39,61 However, owing to the brevity of the 
students’ responses, many of which were listed in 
point-form, this was unlikely to have been a 
significant issue in our study. 
Detailed data concerning the content, format or 
duration of mental health pharmacy education were 
not collected from the eight universities that 
participated in IPSHS. However, on the basis of 
other reports it is reasonable to assume that there 
was considerable variation between universities.62,63 
Internship experience in the pharmacy workplace is 
now a core component of undergraduate education 
in many countries. However, it was not assessed 
whether barriers perceived by students who had 
worked in pharmacies differed from those who had 
not. Previous studies have produced conflicting 
results as to whether internship experience in the 
pharmacy workplace improves students’ attitudes 
toward people with mental health disorders.27,42 Nor 
was it assessed whether the barriers identified 
varied according to the age or gender of the 
respondents, or according to whether the students 
had personal or family experience of mental health 
disorders. The focus of this study was on the 
provision of verbal medication counselling in 
community pharmacies. Future studies may seek to 
explore the use of alternative methods of 




Misconceptions related to mental health disorders 
were common among students in all countries. The 
nature of barriers to medication counselling 
identified varied according the country in which the 
students studied. The responses of students 
highlighted areas in which pharmacy education and 
pharmacy practice may need to be improved. 
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